Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 18/20 | 0.69 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.58 |
| ▸ | DHODH | Q02127 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298581 | 0.90 | PARP1 (0.71) | PARP1PARP2DHODHKDRAURKB | |
| SCHEMBL2292553 | 0.87 | PARP1 (0.74) | PARP1PARP2DHODHKDRAURKB | |
| SCHEMBL2297835 | 0.86 | PARP1 (0.53) | PARP1PARP2DHODHAURKB | |
| SCHEMBL2296359 | 0.83 | PARP1 (0.69) | PARP1PARP2DHODHKDRAURKB | |
| SCHEMBL7137128 | 0.82 | PARP1 (1.00) | PARP1DHODHKDRAURKBAURKA | |
| SCHEMBL2297211 | 0.82 | PARP1 (0.70) | PARP1PARP2DHODHKDRAURKB | |
| SCHEMBL29179976 | 0.82 | PARP1 (0.85) | PARP1DHODHKDRAURKBAURKA | |
| SCHEMBL30811245 | 0.82 | PARP1 (1.00) | PARP1PARP2DHODHKDRAURKB | |
| SCHEMBL29179971 | 0.82 | PARP1 (1.00) | PARP1PARP2DHODHKDRAURKB | |
| SCHEMBL7139308 | 0.81 | PARP1 (1.00) | PARP1DHODHKDRAURKBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999117-B2 | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | ABBVIE INC. | 2011-08-16 | — | — | US | claimed |
| US-20090186877-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | claimed |
| US-20070259937-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES | 2007-11-08 | — | — | US | claimed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-13 | — | — | US | disclosed |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2019-03-28 | — | — | US | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| US-7999117-B2 | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | ABBVIE INC. | 2011-08-16 | — | — | US | disclosed |
| US-20090186877-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
| US-20070259937-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259937-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP4 | PARP1 1/4885PARP2 2/4885DHODH 980/4885 |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | PARP1 418/4885PARP2 422/4885DHODH 1189/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | PARP1 418/4885PARP2 422/4885DHODH 1189/4885 |
| US-20090186877-A1 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP4 | PARP1 1/4885PARP2 2/4885DHODH 980/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | PARP1 418/4885PARP2 422/4885DHODH 1189/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | PARP1 418/4885PARP2 422/4885DHODH 1189/4885 |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DDOST, DCLRE1A, OGG1 | PARP1 248/4885PARP2 196/4885DHODH 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.